{"id":529604,"date":"2021-08-19T06:53:03","date_gmt":"2021-08-19T10:53:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/"},"modified":"2021-08-19T06:53:03","modified_gmt":"2021-08-19T10:53:03","slug":"novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/","title":{"rendered":"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>NovaBay Pharmaceuticals to Distribute Zocular<sup>\u00ae<\/sup> Dry Eye Products<\/b><\/p>\n<p>EMERYVILLE, Calif. &amp; CYPRESS, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.novabay.com%2F&amp;esheet=52479255&amp;newsitemid=20210819005141&amp;lan=en-US&amp;anchor=NovaBay%26%23174%3B+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=c443ef8ac5640ecb2352553ba203708d\">NovaBay<sup>\u00ae<\/sup> Pharmaceuticals, Inc.<\/a> (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products alongside Avenova in NovaBay\u2019s physician-dispensed sales channel. Products sold under the Zocular brand were developed by Okra Limited CEO Peter Pham, MD, a board-certified ophthalmologist, and are all complementary to Avenova. They are formulated with Zokrex\u2122, a patented technology with activated natural okra polysaccharide complexes, and are designed to gently and effectively clear Demodex, scurf and residue from eyelids.\n<\/p>\n<p>\n\u201cWe\u2019ve been searching for additional dry eye products to add to our established sales channels for some time. The Zocular product line is ideal for eyecare specialists seeking effective tools to treat their patients\u2019 dry eye and is a perfect complement to Avenova,\u201d said Justin Hall, NovaBay CEO. \u201cZocular products are formulated with a novel, powerful technology to address inflammation at the eyelid margin. Avenova is the only lid and lash antimicrobial spray to be clinically proven to reduce the bacterial load on skin surfaces surrounding the eyes, thus addressing the underlying cause of bacterial dry eye. Both Avenova and Zocular at-home products are completely safe for regular use.\u201d\n<\/p>\n<p>\nZocular products include easy-to-use in-office and at-home treatment options. The ZocuKit for ZEST<sup>\u00ae <\/sup>(Zocular Eyelid System Technology) is a 10-minute, in-office procedure clinically proven to provide dramatic, immediate and lasting results for patients suffering from dry eye. ZEST requires no capital equipment or topical anesthetic, and is well tolerated by patients. At-home consumer dry eye maintenance products include ZocuWipe<sup>\u2122<\/sup>, a once-daily disposable towel that neutralizes and removes oil, dirt and debris; ZocuFoam<sup>\u2122<\/sup>, a gentle eyelid cleansing and moisturizing foam; and ZocuShield<sup>\u2122<\/sup>, an easy-to-apply gel-filled syringe.\n<\/p>\n<p>\n\u201cAs a dry eye sufferer myself, one of the biggest problems is the time required for any treatment to produce results. We at Okra Limited pioneered the use of natural okra polysaccharides to solve this unmet need \u2013 the ability to deliver immediate and durable clinical improvement within minutes to patients with ocular surface problems,\u201d said Dr. Pham. \u201cLinking the Zokrex polysaccharide technology in Zocular products with Avenova\u2019s pharmaceutical-grade hypochlorous acid provides unmatched treatment efficacy for almost any clinical situation. Our team at Okra is delighted to partner with NovaBay to put this powerful combination of products in the hands of eyecare specialists.\u201d\n<\/p>\n<p>\nTo learn more about Zocular and to order products, eyecare specialists are invited to call 844-ZOCULAR.\n<\/p>\n<p><b>About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics<sup>\u00ae<\/sup><\/b><\/p>\n<p>\nNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on high-quality, differentiated, anti-infective consumer products: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.avenova.com%2F&amp;esheet=52479255&amp;newsitemid=20210819005141&amp;lan=en-US&amp;anchor=Avenova%26%23174%3B&amp;index=2&amp;md5=b7c9e88372eb8f229aa55dd0878297e6\">Avenova\u00ae<\/a>, the premier antimicrobial lid and lash spray, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cellerx.com%2F&amp;esheet=52479255&amp;newsitemid=20210819005141&amp;lan=en-US&amp;anchor=CelleRx%26%23174%3B+Clinical+Reset%26%238482%3B&amp;index=3&amp;md5=379dc1ae85d923daedeccf38a772b967\">CelleRx\u00ae Clinical Reset\u2122<\/a>, a breakthrough product in the beauty category, and NeutroPhase<sup>\u00ae<\/sup> Skin and Wound Cleanser for wound healing. NovaBay\u2019s products are formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid that replicates the antimicrobial chemicals used by white blood cells to fight infection. NovaBay\u2019s hypochlorous acid products do not cause stinging or irritation, are non\u2011toxic and non-sensitizing, making them completely safe for regular use. Avenova is the only commercial hypochlorous acid lid and lash spray product clinically proven to reduce bacterial load on ocular skin surfaces, thus effectively addressing the underlying cause of bacterial dry eye.\n<\/p>\n<p><b>NovaBay Pharmaceuticals Forward-Looking Statements<\/b><\/p>\n<p>\nExcept for historical information herein, matters set forth in this press release are forward\u2011looking within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management\u2019s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current product offerings and marketing efforts, the financial impact of our partnerships, and any future revenue that may result from selling these products, as well as generally the Company\u2019s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Other risks relating to NovaBay\u2019s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay\u2019s latest Form 10-Q\/K filings with the Securities and Exchange Commission, especially under the heading \u201cRisk Factors.\u201d The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210819005141\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210819005141\/en\/<\/a><\/span><\/p>\n<p><b>NovaBay Contacts:<\/b><\/p>\n<p><span class=\"bwuline\">At the Company<br \/>\n<\/span><br \/>Justin Hall<br \/>\n<br \/>Chief Executive Officer and General Counsel<br \/>\n<br \/>510-899-8800<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jhall@novabay.com\">jhall@novabay.com<\/a><\/p>\n<p><span class=\"bwuline\">Investors<br \/>\n<\/span><br \/>LHA Investor Relations<br \/>\n<br \/>Jody Cain<br \/>\n<br \/>310-691-7100<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jcain@lhai.com\">jcain@lhai.com<\/a><\/p>\n<p><b>Okra LLC Contact:<br \/>\n<\/b><br \/>Peter Pham, MD<br \/>\n<br \/>Chief Executive Officer<br \/>\n<br \/>844-962-8527<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:peter.pham@zocular.com\">peter.pham@zocular.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Pharmaceutical Optical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products EMERYVILLE, Calif. &amp; CYPRESS, Texas&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products alongside Avenova in NovaBay\u2019s physician-dispensed sales channel. Products sold under the Zocular brand were developed by Okra Limited CEO Peter Pham, MD, a board-certified ophthalmologist, and are all complementary to Avenova. They are formulated with Zokrex\u2122, a patented technology with activated natural okra polysaccharide complexes, and are designed to gently and effectively clear Demodex, scurf and residue from eyelids. \u201cWe\u2019ve been searching for additional dry eye products to add to our established sales channels for some &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-529604","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products EMERYVILLE, Calif. &amp; CYPRESS, Texas&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products alongside Avenova in NovaBay\u2019s physician-dispensed sales channel. Products sold under the Zocular brand were developed by Okra Limited CEO Peter Pham, MD, a board-certified ophthalmologist, and are all complementary to Avenova. They are formulated with Zokrex\u2122, a patented technology with activated natural okra polysaccharide complexes, and are designed to gently and effectively clear Demodex, scurf and residue from eyelids. \u201cWe\u2019ve been searching for additional dry eye products to add to our established sales channels for some &hellip; Continue reading &quot;NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-19T10:53:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products\",\"datePublished\":\"2021-08-19T10:53:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/\"},\"wordCount\":857,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/\",\"name\":\"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-08-19T10:53:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/","og_locale":"en_US","og_type":"article","og_title":"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products - Market Newsdesk","og_description":"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products EMERYVILLE, Calif. &amp; CYPRESS, Texas&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products alongside Avenova in NovaBay\u2019s physician-dispensed sales channel. Products sold under the Zocular brand were developed by Okra Limited CEO Peter Pham, MD, a board-certified ophthalmologist, and are all complementary to Avenova. They are formulated with Zokrex\u2122, a patented technology with activated natural okra polysaccharide complexes, and are designed to gently and effectively clear Demodex, scurf and residue from eyelids. \u201cWe\u2019ve been searching for additional dry eye products to add to our established sales channels for some &hellip; Continue reading \"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-19T10:53:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products","datePublished":"2021-08-19T10:53:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/"},"wordCount":857,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/","name":"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-08-19T10:53:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210819005141r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-distribute-zocular-dry-eye-products\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NovaBay Pharmaceuticals to Distribute Zocular\u00ae Dry Eye Products"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/529604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=529604"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/529604\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=529604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=529604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=529604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}